Latest news with #GraigSuvannavejh
Yahoo
20-07-2025
- Business
- Yahoo
Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the . On July 16, Mizuho analyst Graig Suvannavejh raised the firm's price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $5 from $4, maintaining an Outperform rating on the shares. A laboratory technician researching a sample of cells in a biotechnology laboratory. The rating update came after the introduction of NMRA-861 on July 9, when Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-861 in healthy adult participants with stable schizophrenia. NMRA-861 is a highly potent and selective positive allosteric modulator (PAM) that Neumora Therapeutics, Inc. (NASDAQ:NMRA) is developing for the treatment of schizophrenia and other neuropsychiatric disorders. Mizuho estimates a US launch in 2034, with risk-unadjusted NMRA-861 sales reaching $1.2 billion in 2037. It also sees a favorable risk/reward at current share levels, supporting the optimistic outlook on Neumora Therapeutics, Inc. (NASDAQ:NMRA). Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biotechnology company that integrates neuroscience and data science to offer a precision medicine approach for brain diseases. Its focus is on advancing medicines for therapeutically relevant targets implicated in CNS diseases. While we acknowledge the potential of NMRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
10-07-2025
- Business
- Business Insider
Mizuho Securities Keeps Their Buy Rating on Immuneering (IMRX)
In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Immuneering, with a price target of $10.00. The company's shares closed today at $4.45. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Harmony Biosciences Holdings, and Corvus Pharmaceuticals. According to TipRanks, Suvannavejh has an average return of -6.5% and a 40.79% success rate on recommended stocks. Currently, the analyst consensus on Immuneering is a Strong Buy with an average price target of $10.88. Based on Immuneering's latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.05 million. In comparison, last year the company had a GAAP net loss of $14.31 million Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMRX in relation to earlier this year. Earlier this month, Diana Hausman, a Director at IMRX bought 5,500.00 shares for a total of $19,835.00.
Business Insider
26-06-2025
- Business
- Business Insider
Mizuho Securities Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report) today and set a price target of $12.00. The company's shares closed today at $2.58. Confident Investing Starts Here: Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Insmed, and Verastem. According to TipRanks, Suvannavejh has an average return of -7.4% and a 40.59% success rate on recommended stocks. Adverum Biotechnologies has an analyst consensus of Strong Buy, with a price target consensus of $17.00. The company has a one-year high of $10.14 and a one-year low of $1.78. Currently, Adverum Biotechnologies has an average volume of 345.4K. Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is neutral on the stock. Last month, Laurent Fischer, the CEO, PRESIDENT AND DIRECTOR of ADVM sold 9,126.00 shares for a total of $18,252.00.
Business Insider
25-06-2025
- Business
- Business Insider
Mizuho Securities Remains a Buy on Corvus Pharmaceuticals (CRVS)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Corvus Pharmaceuticals (CRVS – Research Report) today and set a price target of $11.00. The company's shares closed today at $4.34. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Suvannavejh is an analyst with an average return of -8.4% and a 40.35% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Harmony Biosciences Holdings, and Insmed. Corvus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $13.00.
Yahoo
18-06-2025
- Business
- Yahoo
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
Insmed Inc. (NASDAQ:INSM) is one of the 10 best growth stocks to buy according to billionaires. On June 10, Mizuho analyst Graig Suvannavejh reaffirmed his Outperform rating on Insmed and raised the price target from $96 to $110. The revision follows the encouraging Phase 2b results for Treprostinil Palmitil Inhalation Powder (TPIP) in treating pulmonary arterial hypertension. Suvannavejh describes the data as highly positive, suggesting TPIP could become a leading treatment option in the respective area. A scientist using sophisticated laboratory equipment to analyze a sample of a therapeutic candidate. The analyst believes the trial's success strengthens Insmed's growth outlook and opens the door for further upside to current earnings estimates. The tone of the note reflects the analyst's strong confidence in TPIP's potential and its impact on Insmed's long-term value. Insmed Inc. (NASDAQ:INSM) is a global biopharmaceutical company that develops therapies for serious diseases. It has a commercial product, ARIKAYCE, and a pipeline that includes clinical-stage programs, brensocatib, TPIP, and INS1201, as well as pre-clinical research programs. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
